aTyr Pharma, Inc. (ATYR) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for pulmonary diseases. This report evaluates its Shariah compliance across financial, business activity, and ESG dimensions using global and regional standards. The company demonstrates strong compliance with financial screening criteria, with low debt and negligible non-compliant income. Inclusion in major Shariah indices confirms its suitability for Islamic investment portfolios. Overall, ATYR presents a low-risk, compliant investment opportunity in the healthcare sector.